NCT01094795已完成不适用
A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Sweden Using the ARTIS Register
Bristol-Myers Squibb0 个研究点目标入组 92,635 人开始时间: 2011年3月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 92,635
- 主要终点
- Hospitalized infection
研究概览
简要总结
The primary purpose of this study is to assess incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Resident of Sweden
排除标准
- 未提供
结局指标
主要结局
Hospitalized infection
时间窗: Every 6 months throughout the study
Malignancy (total, lymphoma, lung cancer, breast cancer, colorectal cancer, prostate cancer)
时间窗: Every 6 months throughout the study
Total mortality
时间窗: Every 6 months throughout the study
次要结局
- Autoimmune disorders (lupus, psoriasis, multiple sclerosis)(Every 6 months throughout the study)
研究者
相似试验
已完成
不适用
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) RegisterRheumatoid ArthritisPsoriatic ArthritisNCT05413044Bristol-Myers Squibb140,706
已完成
不适用
Safety Study of Abatacept to Treat Rheumatoid ArthritisRheumatoid ArthritisNCT01247766Bristol-Myers Squibb6,367
已完成
不适用
A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South KoreaEssential HypertensionNCT04470817Celltrion Pharm, Inc.3,438
已完成
不适用
Clinical and Therapeutic Evaluation of the Infection by HIV/AIDSAcquired Immunodeficiency SyndromeNCT02191215Boehringer Ingelheim442
进行中（未招募）
不适用
Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)Rheumatoid ArthritisNCT01088360Bristol-Myers Squibb20,000